Circulating biomarkers of collagen metabolism in cardiac diseases

Circulation

Volumn 121, Issue 14, 2010, Pages 1645-1654

  López, Begoña ^a   González, Arantxa ^a   Díez, Javier ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERSTITIAL COLLAGENASE; PROCOLLAGEN; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN N PROTEINASE; PROPEPTIDE OF PROCOLLAGEN TYPE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TORASEMIDE; UNCLASSIFIED DRUG;

BLOOD LEVEL; CIRCULATION; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; COMORBIDITY; COST BENEFIT ANALYSIS; HEART DISEASE; HEART FAILURE; HEART MUSCLE; HEART MUSCLE CELL; HISTOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOASSAY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ALDOSTERONE; BIOLOGICAL MARKERS; CARRIER PROTEINS; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; HEART DISEASES; HEART FAILURE; HUMANS; MATRIX METALLOPROTEINASE 1; MYOCARDIUM; MYOCYTES, CARDIAC; PEPTIDE FRAGMENTS; PROCOLLAGEN; STROKE VOLUME; TRANSFORMING GROWTH FACTOR BETA;

EID: 77950940268     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.912774     Document Type: Review

References (95)

1. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358: 2148-2159.
2. Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol. 1987;252(pt 1):C1-C9.
3. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
4. Nimmi ME. Fibrillar collagens: their biosynthesis, molecular structure, and mode of assembly. In: Zern MA, Reid LM, eds. Extracellular Matrix. New York, NY: Marcel Decker; 1993:121-148.
5. Jensen LT, Host NB. Collagen: scaffold for repair or execution. Cardiovasc Res. 1997;33:535-539.
6. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11:1696-1701.
7. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993;39:635-640.
8. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.
9. 2+. FEBS Lett. 1988;238: 343-346.
10. 2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67: 2257-2265.
11. Pickart L, Thaler MM. Growth-modulating tripeptide (glycylhistidyl- lysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. J Cell Physiol. 1980;102:129-139.
12. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol. 1989;13:1637-1652.
13. Bishop JE, Laurent GJ. Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J. 1995;16(suppl):38-44.
14. Janicki JS, Brower GL, Gardner JD, Chancey AL, Stewart JA Jr. The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev. 2004;9:33-42.
15. Brower GL, Gardner JD, Forman MF, Murray DB, Vloshenyuk T, Levick SP, Janicki JS. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg. 2006;30: 604-610.
16. Spinale FG. Myocardial matrix remodeling and the matrix metallopro-teinases: influence on cardiac form and function. Physiol Rev. 2007;87: 1285-1342.
17. Graham HK, Horn M, Trafford AW. Extracellular matrix profiles in the progression to heart failure. Acta Physiol. 2008;194:3-21.
18. Herpel E, Pritsch M, Koch A, Dengler TJ, Schirmacher P, Schnabel PA. Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy. Histopathology. 2006;48:736-747.
19. Gonzalez A, Lopez B, Ravassa S, Beaumont J, Arias T, Hermida N, Zudaire A, Díez J. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc Res. 2009;81:509-518.
20. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martínez Ubago JL, Díez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004;110:1263-1268.
21. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martínez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Díez J. Serum carboxy-terminal propeptide procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-1735.
22. Díez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martínez-Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512-2517.
23. Díez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation. 1995;91:1450-1456.
24. Lopez B, Gonzalez A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensives with heart failure. J Am Coll Cardiol. 2006;48:89-96.
25. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005;112:2940-2945.
26. Demir M, Acartürk E, Inal T, Attila G, Donmez Y, Avkarogullari M, Cayli M. Procollagen type I carboxy-terminal peptide shows left ventricular hypertrophy and diastolic dysfunction in hypertensive patients. Cardiovasc Pathol. 2007;16:69-74.
27. Lopez B, Gonzalez A, Beaumont J, Querejeta R, Larman M, Díez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50: 859-867.
28. Lopez B, Querejeta R, Varo N, Laviades C, Querejeta R, Díez J. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104:286-291.
29. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028-2035. (Pubitemid 38686797)
30. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, Conlon C, Patle A, Donnelly SC, McDonald K. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009;11:191-197.
31. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, Pacher R, Grimm M, Pribill I, Eichler HG, Glogar HD. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75:913-918.
32. Poulsen SH, Andersen NH, Heickendorff L, Mogensen CE. Relation between plasma amino-terminal propeptide of procollagen type III and left ventricular longitudinal strain in essential hypertension. Heart. 2005; 91:624-629.
33. Díez J, Panizo A, Gil MJ, Monreal I, Hernández M, Pardo Mindán J. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation. 1996;93: 1026-1032.
34. Fielitz J, Leuschner M, Zurbrügg HR, Hannack B, Pregla R, Hetzer R, Regitz-Zagrosek V. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med. 2004;82:809-820.
35. Thomas CV, Coker ML, Zeliner JL, Handy JR, Crumbley AJ III, Spinale FG. Increased matrix metalloproteinase activity and selective upregu-lation in LV myocardium from patients with end-stage dilated cardiomy-opathy. Circulation. 1998;97:1708-1715.
36. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zeliner JL, Crumbley AJ. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102: 1944-1999.
37. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension. 2002; 40:136-141.
38. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. Matrix metallopro-teinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089-2096.
39. Frantz S, Störk S, Michels K, Eigenthaler M, Ertl G, Bauersachs J, Angermann CE. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail. 2008;10:388-395.
40. Fassbach M, Schwartzkopff B. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol. 2005;94:328-335.
41. Klotz S, Foronjy RF, Dickstein ML, Gu A, Garrelds IM, Danser AH, Oz MC, D'Armiento J, Burkhoff D. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation. 2005;112:364-374.
42. Bruggink AH, van Oosterhout MF, de Jonge N, Ivangh B, van Kuik J, Voorbij RH, Cleutjens JP, Gmelig-Meyling FH, de Weger RA. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant. 2006;25:1091-1098.
43. Roldán V, Marín F, Gimeno JR, Ruiz-Espejo F, González J, Feliu E, García-Honrubia A, Saura D, de la Morena G, Valdés M, Vicente V. Matrix metalloproteinases and tissue remodeling in hypertrophic cardio-myopathy. Am Heart J. 2008;156:85-91.
44. Risteli J, Risteli L. Assays of type I procollagen domains and collagen fragments: problems to be solved and future trends. Scand J Clin Lab Invest Suppl. 1997;227:105-113.
45. Smedsrød B, Melkko J, Risteli L, Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J. 1990;271:345-350.
46. Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrød B. Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med. 1994;179:405-412.
47. Remacle AG, Chekanov AV, Golubkov VS, Savinov AY, Rozanov DV, Strongin AY. O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP). J Biol Chem. 2006;281: 16897-16905.
48. Emonard H, Bellon G, de Diesbach P, Mettlen M, Hornebeck W, Courtoy PJ. Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein (LRP): a new function for an "old friend." Biochimie. 2005;8:369-376.
49. Sottrup-Jensen L, Birkedal-Hansen H. Human fibroblast collagenase-alpha-macroglobulin interactions: localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem. 1989; 264:393-401.
50. Trivedi P, Risteli J, Risteli L, Hindmarsh PC, Brook CG, Mowat AP. Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Ped Res. 1991;30:276-280.
51. Wang TJ, Larson MG, Benjamin EJ, Siwik DA, Safa R, Guo CY, Corey D, Sundstrom J, Sawyer DB, Colucci WS, Vasan RS. Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community. Am Heart J. 2007;154: 291-297.
52. Sundstrom J, Evans JC, Benjamin EJ, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Wilson PW, Vasan RS. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart Study. Eur Heart J. 2004;25:1509-1516.
53. Ishikawa J, Kario K, Matsui Y, Shibasaki S, Morinari M, Kaneda R, Hoshide S, Eguchi K, Hojo Y, Shimada K. Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy. Hypertens Res. 2005; 28:995-1001.
54. McNulty M, Mahmud A, Spiers P, Feely J. Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. J Hum Hypertens. 2006;20:867-873.
55. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer. 2000;88:2919-2926.
56. Christenson RH. Biomarkers of bone metabolism: an overview. Clin Biochem. 1997;30:573-593.
57. Grigorescu M. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis. 2006;15:149-159.
58. Urena P, de Vernejoul M-C. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999;55:2141-2156.
59. Nakamura RN. Progress in use of biochemical and biological markers for evaluation of rheumatoid arthritis. J Clin Lab Anal. 2000;14:305-313.
60. Thickett DR, Poole AR, Millar AB. The balance between collagen synthesis and degradation in diffuse lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:27-33.
61. Muller-Brunotte R, Kahan T, Lopez B, Edner M, Gonzalez A, Díez J, Malmqvist K. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). J Hypertens. 2007;25:1958-1966. (Pubitemid 47356638)
62. Ciulla MM, Paliotti R, Esposito A, Díez J, Lopez B, Dahlof B, Nicholls MG, Smith RD, Gilles L, Magrini F, Zanchetti A. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004;110:552-557.
63. Kawasaki D, Kosugi K, Waki H, Yamamoto K, Tsujino T, Masuyama T. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients: reversal by chronic angiotensin II type 1A receptor blockade. Circ J. 2007;71:524-529.
64. Kawano H, Toda G, Nakamizo R, Koide Y, Seto S, Yano K. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J. 2005;69:1244-1248.
65. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES): Rales Investigators. Circulation. 2000;102:2700-2706.
66. Berry C, Murphy NF, De Vito G, Galloway S, Seed A, Fisher C, Sattar N, Vallance P, Hillis WS, McMurray J. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail. 2007;9:429-434.
67. Shah NC, Pringle SD, Donnan PT, Struthers AD. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens. 2007;25:2345-2351.
68. Iraqi W, Rossignol P, Fay R, Nue'e J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the EPHESUS study. Circulation. 2009;119: 2471-2479.
69. Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, Díez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98:535-540.
70. Tziakas DN, Chalikias GK, Stakos DA, Papazoglou D, Papanas N, Papatheodorou K, Chatzikyriakou SV, Kotsiou S, Maltezos E, Boudoulas H. Effect of angiotensin-converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension. Expert Opin Pharmacother. 2007; 8:2225-2234.
71. Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L. Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest. 2002;32:581-589.
72. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574-1580.
73. van den Borne SW, Isobe S, Verjans JW, Petrov A, Lovhaug D, Li P, Zandbergen HR, Ni Y, Frederik P, Zhou J, Arbo B, Rogstad A, Cuth-bertson A, Chettibi S, Reutelingsperger C, Blankesteijn WM, Smits JF, Daemen MJ, Zannad F, Vannan MA, Narula N, Pitt B, Hofstra L, Narula J. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol. 2008;52:2017-2028.
74. Radovan J, Vaclav P, Petr W, Jan C, Michal A, Richard P, Martina P. Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction. Mol Cell Biochem. 2006;293:71-78.
75. Takino T, Nakamura M, Hiramori K. Circulating levels of carboxy-terminal propeptide of type I procollagen and left ventricular remodeling after myocardial infarction. Cardiology. 1999;91:81-86.
76. Cerisano G, Parodi G, Dovellini EV, Migliorini A, Tommasi M, Raspanti S, Buonamici P, Taddeucci E, Valenti R, Antoniucci D. Time course of serum collagen types I and III metabolism products after reperfused acute myocardial infarction in patients with and without systemic hypertension. J Hum Hypertens. 2009;23:40-47.
77. Cerisano G, Pucci PD, Sulla A, Tommasi M, Raspanti S, Santoro GM, Antoniucci D. Relation between plasma brain natriuretic peptide, serum indexes of collagen type I turnover, and left ventricular remodeling after reperfused acute myocardial infarction. Am J Cardiol. 2007;99:651-656.
78. McGavigan AD, Maxwell PR, Dunn FG. Serological evidence of altered collagen homeostasis reflects early ventricular remodeling following acute myocardial infarction. Int J Cardiol. 2006;111:267-274.
79. Uusimaa P, Risteli J, Niemelä M, Lumme J, Ikäheimo M, Jounela A, Peuhkurinen K. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation. 1997;96:2565-2572. (Pubitemid 27451347)
80. Jensen LT, Hørslev-Petersen K, Toft P, Bentsen KD, Grande P, Simonsen EE, Lorenzen I. Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation. 1990;81: 52-57.
81. Bonnet J, Garderes PE, Aumailley M, Moreau C, Gouverneur G, Benchimol D, Crockett R, Larrue J, Bricaud H. Serum type III pro-collagen peptide levels in coronary artery disease (a marker of atherosclerosis). Eur J Clin Invest. 1988;18:18-21.
82. Radauceanu A, Moulin F, Djaballah W, Marie PY, Alla F, Dousset B, Virion JM, Capiaumont J, Karcher G, Aliot E, Zannad F. Residual stress ischaemia is associated with blood markers of myocardial structural remodelling. Eur J Heart Fail. 2007;9:370-376.
83. Halapas A, Zacharoulis A, Theocharis S, Karavidas A, Korres D, Pap-adopoulos K, Katopodis H, Stavropoulou A, Lembessis P, Xiromeritis C, Zacharoulis A, Koutsilieris M. Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction. Clin Chem Lab Med. 2008;46: 510-516.
84. Soejima H, Ogawa H, Sakamoto T, Miyamoto S, Kajiwara I, Kojima S, Hokamaki J, Sugiyama S, Yoshimura M, Suefuji H, Miyao Y, Fujimoto K, Miyagi H, Kishikawa H. Increased serum matrix metalloproteinase-1 concentration predicts advanced left ventricular remodeling in patients with acute myocardial infarction. Circ J. 2003;67:301-304.
85. Hirohata S, Kusachi S, Murakami M, Murakami T, Sano I, Watanabe T, Komatsubara I, Kondo J, Tsuji T. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart. 1997;78: 278-284.
86. Suzuki H, Kusuyama T, Sato R, Yokota Y, Tsunoda F, Sato T, Shoji M, Iso Y, Koba S, Katagiri T. Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction. Eur J Clin Invest. 2008;38:166-173.
87. Papadopoulos DP, Moyssakis I, Makris TK, Poulakou M, Stavroulakis G, Perrea D, Votteas VE. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction. Eur Cytokine Netw. 2005;16: 152-160.
88. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888-895.
89. Nakahara T, Takata Y, Hirayama Y, Asano K, Adachi H, Shiokawa G, Sumi T, Ogawa T, Yamashina A. Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. Circ J. 2007;71:716-721.
90. Laviades C, Mayor G, Díez J. Treatment with lisinopril normalizes serum concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. Am J Hypertens. 1994;7:52-58.
91. Valencia Serrano F, López Salazar B, Gomez-Doblás JJ, Rodriguez Bailon I, Porras C, Melero JM, de Teresa Galván E, D́?ez Mart́?nez J. Non invasive assessment of myocardial fibrosis in severe aortic stenosis patients. European Heart J. 2007;28:653.
92. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail. 2002;4:439-444.
93. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 1998;98:1728-1734.
94. González-Vílchez F, Ayuela J, Ares M, Pi J, Castillo L, Martín-Durán R. Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients. Int J Cardiol. 2005;101:53-58.
95. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M, D'Alessandro G, Cacace A, Ciampi Q, Chiariello M. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation. 2003;108:1455-1460.